Alina Basnet, MD
Hematology · Syracuse, NYNPI 1871914465
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,320 of the $4,645 with a category attached, or 71.5%. 25 manufacturers reported payments, led by AstraZeneca at 57.9% of the total. 2025 is the largest year on record at $2,973, more than ten times the $123 reported in 2019.
Across 51 payments — averaging $91.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Bayer$770
- AVEO Pharmaceuticals, Inc.$298
- Sirtex Medical Inc$123
- Merck$98
- E.r. Squibb & Sons, L.L.C.$80
- plus $584 from 19 others
Across 74 payments — averaging $8665.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$276K
- Genentech, Inc.$128K
- Janssen Research & Development, LLC$89K
- Seagen Inc.$68K
- Helsinn Healthcare SA$51K
- Sumitomo Pharma America, Inc.$26K
- plus $4K from 3 others
What the payments were for
- Consulting fees$3,32071%
- Food & beverage$1,04623%
- Education$2796%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 7 | $2,691 |
| Bayer | 2 | $770 |
| AVEO Pharmaceuticals, Inc. | 5 | $298 |
| Sirtex Medical Inc | 1 | $123 |
| Merck | 5 | $98 |
| E.r. Squibb & Sons, L.L.C. | 4 | $80 |
| Johnson & Johnson | 3 | $61 |
| Lilly USA, LLC | 2 | $47 |
| GSK | 2 | $42 |
| Daiichi Sankyo Inc. | 2 | $40 |
| Puma Biotechnology, Inc. | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $35 |
| AbbVie | 2 | $33 |
| Pfizer | 2 | $33 |
| Geron Corporation | 1 | $28 |
| EMD Serono, Inc. | 1 | $27 |
| Array Biopharma Inc | 1 | $25 |
| Stemline Therapeutics Inc. | 1 | $25 |
| Incyte Corporation | 1 | $24 |
| Exelixis Inc. | 1 | $24 |
| Tempus AI, Inc | 1 | $24 |
| Adaptive Biotechnologies Corporation | 1 | $23 |
| Beone Medicines USA, Inc. | 1 | $22 |
| Eisai Inc. | 1 | $17 |
| Bristol Myers Squibb | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TAGRISSO$2,050
- Nubeqa$745
- IMFINZI$525
- SIR-Spheres Microspheres$123
How this compares
$4,645 in reported general payments places this provider in the 65th percentile of 157 hematology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 29 | $369,560 |
| NubeqaDarolutamide | 24 | $260,806 |
| TagrissoOsimertinib Mesylate | 11 | $179,066 |
| LynparzaOlaparib | 12 | $130,023 |
| Abiraterone Acetate | 125 | $79,864 |
| OrgovyxRelugolix | 29 | $77,013 |
| XareltoRivaroxaban | 18 | $9,558 |
| Prednisone | 157 | $470 |
| Prochlorperazine Maleate | 41 | $464 |
| Oxycodone Hcl | 28 | $460 |
| Dexamethasone | 27 | $375 |
| Potassium Chloride | 36 | $337 |
| Ondansetron Hcl | 52 | $294 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $289 |
| Levothyroxine Sodium | 54 | $251 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada, Xarelto | $61 | $379,11947 claims |
| AstraZenecaTagrisso, Lynparza | $2,691 | $309,08923 claims |
| BayerNubeqa | $770 | $260,80624 claims |
| Lilly USA, LLCOlanzapine | $47 | $5111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 157 hematology providers in New York.
Other hematology in Syracuse
- Barry CollerNew York$7.9M
- Allyson OceanNew York$1.4M
- Ahmed SawasNew York$618K
- Jeffrey ZwickerNew York$561K
- Dan DouerNew York$477K
- Ran ReshefNew York$468K
- Faith DaviesNew York$307K
- Michael MauroNew York$229K
- Richard FurmanNew York$208K
- Ann JakubowskiNew York$123K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.